Regenerative Medicine and Stem Cells Technologies

Because mice do not respond to immunomodulatory drugs (IMiDs), preclinical therapeutic and safety studies of the effects of IMiDs have not been possible in existing types of mice. This has led to an inability to accurately assess the mechanism of these drugs in mice.

A new study in STEM CELLS Translational Medicine indicates mesenchymal stem cells (MSCs) are a safe and innovative option to heal normal tissue following radiotherapy. Alain Chapel, Ph.D., and Annette Larsen, DVM, Ph.D., of the Institut National de la Santé et de la Recherche Médicale (INSERM) in France led the team that conducted this research.

Researchers have developed a way to grow human platelets in the laboratory from stem cells derived from fat tissue. The achievement, reported today in the journal Blood, suggests manufactured platelets could eventually reduce the reliance on donated platelets to help patients with cancer and other disorders.

A team of researchers from the Centre for Biomedical Technology (CTB) at Universidad Politécnica de Madrid (UPM) in collaboration with the Universidad Complutense de Madrid (UCM), the Instituto Cajal and the Hospital Clínico San Carlos has developed an innovative treatment to repair damaged brain tissues. Thanks to the implantation of encapsulated stem cells in an innocuous biomaterial and fully biocompatible (silk fibroin), researchers have achieved the functional recovery of mice after suffering an induced brain stroke.

A study recently published in STEM CELLS Translational Medicine(SCTM) describes a new cell therapy that shows promise in treating cirrhosis of the liver. The treatment, combination of mesenchymal stem cells and induced bone marrow-derived macrophages, reduced fibrosis and promoted regeneration of cirrhosis-damaged liver in tests on mice.

Tumor cells can adapt dynamically to changing conditions thanks to their ability to reactivate a cellular process that is central to embryonic development. This allows the cells to alter their molecular properties and to acquire new capabilities.

As we age, our bodies undergo biological changes that cause a decline in the function of our cells and tissues. However, most studies attempting to identify molecules involved age-related dysfunctions have focused only on mechanisms based on mRNA transcription, a very important step in gene expression, but nonetheless only part of the complex regulatory mechanisms in our cells.

Researchers at the University of Toronto and UC San Francisco have discovered that the intestine is the source of immune cells that reduce brain inflammation in people with multiple sclerosis (MS), and that increasing the number of these cells blocks inflammation entirely in a preclinical model of the disease.

A clinical stage biotechnology company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that IDCT has passed the initial planned safety review of its Phase I/II trial evaluating the allogeneic, injectable disc cell therapy in patients with mild to moderate degenerative disc disease (DDD).

Scientists have succeeded for the first time in directly reprogramming human blood cells into a previously unknown type of neural stem cell. These induced stem cells are similar to those that occur during the early embryonic development of the central nervous system.